333 related articles for article (PubMed ID: 25326090)
1. Pharmacokinetics of total and unbound darunavir in HIV-1-infected pregnant women.
Colbers A; Moltó J; Ivanovic J; Kabeya K; Hawkins D; Gingelmaier A; Taylor G; Weizsäcker K; Sadiq ST; Van der Ende M; Giaquinto C; Burger D;
J Antimicrob Chemother; 2015 Feb; 70(2):534-42. PubMed ID: 25326090
[TBL] [Abstract][Full Text] [Related]
2. Atazanavir exposure is effective during pregnancy regardless of tenofovir use.
Colbers A; Hawkins D; Hidalgo-Tenorio C; van der Ende M; Gingelmaier A; Weizsäcker K; Kabeya K; Taylor G; Rockstroh J; Lambert J; Moltó J; Wyen C; Sadiq ST; Ivanovic J; Giaquinto C; Burger D;
Antivir Ther; 2015; 20(1):57-64. PubMed ID: 24992294
[TBL] [Abstract][Full Text] [Related]
3. Use of darunavir/ritonavir once daily in treatment-naive pregnant woman: pharmacokinetics, compartmental exposure, efficacy and safety.
Ivanovic J; Bellagamba R; Nicastri E; Signore F; Vallone C; Tempestilli M; Tommasi C; Mazzitelli L; Narciso P
AIDS; 2010 Apr; 24(7):1083-4. PubMed ID: 20386380
[No Abstract] [Full Text] [Related]
4. Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily.
Zorrilla CD; Wright R; Osiyemi OO; Yasin S; Baugh B; Brown K; Coate B; Verboven P; Mrus J; Falcon R; Kakuda TN
HIV Med; 2014 Jan; 15(1):50-6. PubMed ID: 23731450
[TBL] [Abstract][Full Text] [Related]
5. Treatment simplification to once daily darunavir/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients.
Moltó J; Valle M; Santos JR; Mothe B; Miranda C; Cedeño S; Negredo E; Yritia M; Videla S; Barbanoj MJ; Clotet B
Antivir Ther; 2010; 15(2):219-25. PubMed ID: 20386077
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir.
Kakuda TN; Brochot A; Tomaka FL; Vangeneugden T; Van De Casteele T; Hoetelmans RM
J Antimicrob Chemother; 2014 Oct; 69(10):2591-605. PubMed ID: 24951533
[TBL] [Abstract][Full Text] [Related]
7. Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women.
Conradie F; Zorrilla C; Josipovic D; Botes M; Osiyemi O; Vandeloise E; Eley T; Child M; Bertz R; Hu W; Wirtz V; McGrath D
HIV Med; 2011 Oct; 12(9):570-9. PubMed ID: 21569187
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients.
Boffito M; Miralles D; Hill A
HIV Clin Trials; 2008; 9(6):418-27. PubMed ID: 19203907
[TBL] [Abstract][Full Text] [Related]
9. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic study of dual therapy with raltegravir 400 mg twice daily and Darunavir/Ritonavir 800/100 mg once daily in HIV-1-infected patients.
Martínez-Rebollar M; Muñoz A; Pérez I; Hidalgo S; Brunet M; Laguno M; González A; Calvo M; Loncà M; Blanco JL; Martínez E; Gatell JM; Mallolas J
Ther Drug Monit; 2013 Aug; 35(4):552-6. PubMed ID: 23851911
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected Women.
Stek A; Best BM; Wang J; Capparelli EV; Burchett SK; Kreitchmann R; Rungruengthanakit K; Cressey TR; Mofenson LM; Smith E; Shapiro D; Mirochnick M
J Acquir Immune Defic Syndr; 2015 Sep; 70(1):33-41. PubMed ID: 25950206
[TBL] [Abstract][Full Text] [Related]
12. The pharmacokinetics, safety and efficacy of boosted saquinavir tablets in HIV type-1-infected pregnant women.
van der Lugt J; Colbers A; Molto J; Hawkins D; van der Ende M; Vogel M; Wyen C; Schutz M; Koopmans P; Ruxrungtham K; Richter C; Burger D;
Antivir Ther; 2009; 14(3):443-50. PubMed ID: 19474478
[TBL] [Abstract][Full Text] [Related]
13. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.
Clotet B; Feinberg J; van Lunzen J; Khuong-Josses MA; Antinori A; Dumitru I; Pokrovskiy V; Fehr J; Ortiz R; Saag M; Harris J; Brennan C; Fujiwara T; Min S;
Lancet; 2014 Jun; 383(9936):2222-31. PubMed ID: 24698485
[TBL] [Abstract][Full Text] [Related]
14. Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1.
Pinnetti C; Tamburrini E; Ragazzoni E; De Luca A; Navarra P
Antivir Ther; 2010; 15(1):127-9. PubMed ID: 20167999
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.
Clotet B; Bellos N; Molina JM; Cooper D; Goffard JC; Lazzarin A; Wöhrmann A; Katlama C; Wilkin T; Haubrich R; Cohen C; Farthing C; Jayaweera D; Markowitz M; Ruane P; Spinosa-Guzman S; Lefebvre E;
Lancet; 2007 Apr; 369(9568):1169-78. PubMed ID: 17416261
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, safety and efficacy of ritonavir-boosted atazanavir (300/100 mg once daily) in HIV-1-infected pregnant women.
Lê MP; Mandelbrot L; Descamps D; Soulié C; Ichou H; Bourgeois-Moine A; Damond F; Lariven S; Valantin MA; Landman R; Faucher P; Tubiana R; Duro D; Meier F; Legac S; Bourse P; Mortier E; Dommergues M; Calvez V; Matheron S; Peytavin G
Antivir Ther; 2015; 20(5):507-13. PubMed ID: 25599649
[TBL] [Abstract][Full Text] [Related]
17. The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women.
Colbers AP; Hawkins DA; Gingelmaier A; Kabeya K; Rockstroh JK; Wyen C; Weizsäcker K; Sadiq ST; Ivanovic J; Giaquinto C; Taylor GP; Moltó J; Burger DM;
AIDS; 2013 Mar; 27(5):739-48. PubMed ID: 23169329
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and Safety of Darunavir/Ritonavir in HIV-Infected Pregnant Women.
Khoo S; Peytavin G; Burger D; Hill A; Brown K; Moecklinghoff C; La Porte C; Hadacek MB
AIDS Rev; 2017; 19(1):16-23. PubMed ID: 28182610
[TBL] [Abstract][Full Text] [Related]
19. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
Mills AM; Nelson M; Jayaweera D; Ruxrungtham K; Cassetti I; Girard PM; Workman C; Dierynck I; Sekar V; Abeele CV; Lavreys L
AIDS; 2009 Aug; 23(13):1679-88. PubMed ID: 19487905
[TBL] [Abstract][Full Text] [Related]
20. Lopinavir/ritonavir trough concentrations with the tablet formulation in HIV-1-infected women during the third trimester of pregnancy.
Calza L; Manfredi R; Trapani F; Salvadori C; Colangeli V; Borderi M; Grossi G; Motta R; Viale P
Scand J Infect Dis; 2012 May; 44(5):381-7. PubMed ID: 22263609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
